Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 17/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.48 |
| ▸ | ABL1 | P00519 | 6/20 | 0.47 |
| ▸ | YES1 | P07947 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5996220 | 0.90 | SRC (0.56) | SRCPDGFRBABL1YES1KDR | |
| SCHEMBL5997659 | 0.87 | SRC (0.48) | SRCPDGFRBABL1KDRCYP3A4 | |
| SCHEMBL5450772 | 0.82 | SRC (0.48) | SRCPDGFRBABL1YES1KDR | |
| SCHEMBL5450769 | 0.82 | SRC (0.48) | SRCPDGFRBABL1YES1KDR | |
| SCHEMBL5998284 | 0.81 | LCK (0.57) | SRCPDGFRBABL1YES1KDR | |
| SCHEMBL2498334 | 0.81 | BTK (0.61) | SRCPDGFRBABL1KDREPHB4 | |
| SCHEMBL5997326 | 0.81 | KMT2A (0.46) | ABL1KDRCYP3A4KMT2A | |
| SCHEMBL5997190 | 0.78 | SRC (0.56) | SRCPDGFRBABL1YES1KDR | |
| SCHEMBL5997067 | 0.78 | SRC (0.55) | SRCPDGFRBABL1YES1EPHB4 | |
| SCHEMBL2495242 | 0.77 | BTK (0.64) | SRCPDGFRBABL1KDREPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | DTYMK, SRC, DCK | SRC 2/4885PDGFRB 97/4885ABL1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.